ArticleThe Lancet. Respiratory medicine2020
Antihypertensive drugs and risk of COVID-19?
Article in The Lancet. Respiratory medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Effect of heart failure on the outcome of COVID-19 - A meta analysis and systematic review.The American journal of emergency medicine · 2021Pooled it
- Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers.Diabetes & metabolic syndromePooled it
- Enzymes in the time of COVID-19: An overview about the effects in the human body, enzyme market, and perspectives for new drugs.Medicinal research reviews · 2022Review
- Updates on Palliative Medicine in the COVID-19 Era.Journal of clinical medicine · 2022Article
- SARS-COV-2, infection, transmission, transcription, translation, proteins, and treatment: A review.International journal of biological macromolecules · 2021Review
- Analgesic Drugs and COVID-19.Journal of clinical medicine · 2021Article
- Hypertension, diabetes mellitus, and cerebrovascular disease predispose to a more severe outcome of COVID-19.Archives of medical sciences. Atherosclerotic diseases · 2021Article
- Antecedent Administration of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Antagonists and Survival After Hospitalization for COVID-19 Syndrome.Journal of the American Heart Association · 2020Observational
- Coronavirus disease 2019 (COVID-19) and the renin-angiotensin system: A closer look at angiotensin-converting enzyme 2 (ACE2).Annals of clinical biochemistry · 2020Review
- Clinical characteristics of COVID-19 in children: Are they similar to those of SARS?Pediatric pulmonology · 2020Review
- Systematic Review and Pharmacological Considerations for Chloroquine and Its Analogs in the Treatment for COVID-19.Frontiers in pharmacology · 2020Review
- Fulminant Acute Kidney Injury in a Young Patient with Novel Coronavirus 2019.Cardiorenal medicine · 2020Article
Corrections and comments
- Commented on by
- Comment on
- Comment on
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.